Revolution Medicines (NASDAQ: RVMD) — Company Overview, News & Financial Data
Revolution Medicines develops targeted therapies for cancer, focusing on precision oncology and disrupting pathways critical to tumor survival.
Revolution Medicines
Revolution Medicines is a clinical-stage oncology company focused on discovering and developing novel targeted therapies for patients with RAS-addicted cancers. The company leverages its proprietary tri-complex platform to target the active RAS(ON) state of RAS proteins, which drive roughly thirty percent of human cancer diagnoses. Its research and development pipeline includes investigational oral small-molecule inhibitors designed as monotherapies and combination regimens for solid tumors. Key clinical programs target mutant forms such as RAS G12C, RAS G12D, and broad-spectrum RAS variants across non-small cell lung cancer, pancreatic cancer, and colorectal cancer.
Snapshot
Operations
Products and/or services of Revolution Medicines
- RAS Multi-Selective Inhibitors: Investigational oral small-molecule therapies targeting active RAS(ON) proteins across multiple oncogenic mutations, undergoing clinical trials for advanced solid tumors including pancreatic ductal adenocarcinoma and non-small cell lung cancer.
- RAS G12C-Selective Inhibitors: Targeted investigational oral compounds designed to bind directly to active KRAS G12C mutants via tri-complex formation, currently evaluated in clinical trials as monotherapy and in targeted combination therapies for solid tumors.
- RAS G12D-Selective Inhibitors: Oral small-molecule candidates specifically targeting the active state of KRAS G12D mutated proteins, currently evaluated in ongoing clinical trials for gastrointestinal and lung malignancies, including pancreatic ductal adenocarcinoma and colorectal carcinoma.
- Tri-Complex Discovery Platform: Proprietary structure-based drug discovery platform utilizing intracellular immunophilin chaperones, such as cyclophilin A, to non-covalently engage and inhibit previously undruggable active RAS(ON) signaling complexes across various human cancer cell models.
- Mutant-Selective Preclinical Pipeline: Early-stage research and discovery programs focused on developing targeted inhibitors against distinct oncogenic RAS variants, including G12V, G13D, and Q61 mutations, to broaden coverage across RAS-driven oncology indications.
- Combination Regimen Clinical Programs: Development initiatives evaluating investigational RAS(ON) candidates in combination with existing standard-of-care therapies, checkpoint inhibitors, and complementary targeted agents to prevent therapeutic resistance and improve anti-tumor responses.
Revolution Medicines executive team
- Mark A. GoldsmithCEO, President & Chairman
- Jack AndersChief Financial Officer
- Margaret A. HornChief Operating Officer
- Jeffrey CisliniSenior VP, General Counsel & Corporate Secretary
- Stephen M. KelseySenior Advisor
- Martin D. BurkeCo-Founder & Chairman of Scientific Advisory Board
- Michael A. FischbachAcademic Co-Founder & Member of Scientific Advisory Board
- Kevan M. ShokatAcademic Co-Founder & Member of Scientific Advisory Board
- Walter ReiherChief Information Officer
- Jan SmithChief Scientific Officer
Latest news about Revolution Medicines
BeOne and Revolution Medicines expand oncology partnership
United StatesRevolution Medicines reveals zoldonrasib 82% response rate
United StatesRevolution Medicines starts phase 3 trial of zoldonrasib in pancreatic cancer
United StatesRevolution Medicines surges on unprecedented survival data in Phase 3 pancreatic cancer trial
United States
Key financials
Reported results for Revolution Medicines, in USD.
- Market cap
- 41B
- Revenue (TTM)
- 742K
- P/E ratio
- —
- EPS (diluted, TTM)
- -8.9
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -1.2B | -1.1B | |
| 0 | -689.5M | -600.1M | |
| 11.6M | -487.2M | -436.4M | |
| 35.4M | -258.3M | -248.7M |